BD Completes Diabetes Care Business Spinoff to Focus on Core Business

By HospiMedica International staff writers
Posted on 04 Apr 2022

Image: BD Nano 2nd Gen Pen Needles (Photo courtesy of Embecta Corp.)

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has completed its spinoff of Embecta Corp. (Franklin Lakes, NJ, USA), which holds BD's former Diabetes Care business and is now one of the largest pure-play diabetes management companies in the world.

The spinoff of embecta is part of BD's 2025 strategy, which includes its three strategic pillars of Grow, Simplify and Empower. The strategic rationale for the spinoff was to create two, independent companies with attractive long-term value for BD shareholders and enhanced strategic, operational and financial characteristics. Each company will focus on its core business and product portfolios, with BD maintaining its positions across its BD Medical, BD Life Sciences and BD Interventional segments. As a producer of diabetes injection devices, embecta will focus on investing in both organic and inorganic growth opportunities and improving the lives of people living with diabetes.

"The completion of this spinoff is a significant achievement for both BD and embecta," said Tom Polen, chairman, CEO and president of BD. "While BD is proud of its heritage in the diabetes care category, we are just as excited to see our legacy advanced by embecta as a newly independent, publicly-traded corporation. Moving forward, each of our organizations will be able to focus on investment and innovation in our respective core businesses, support our customers and the patients they serve, drive strategic growth and enhance long-term shareholder value."

Related Links:
Becton, Dickinson and Company
Embecta Corp.